Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

NEXGEL, Inc. NXGLW NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
34/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

NEXGEL, Inc. (NXGLW) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $0.05. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: NXGLW trades at a trailing Price-to-Earnings (P/E) of -1.6 (S&P 500 average ~25).

Financials: revenue is $11M, +81.2%/yr average growth. Net income is $3M (loss), growing at +17.8%/yr. Net profit margin is -26.3% (negative). Gross margin is 39.5% (+27 pp trend).

Balance sheet: total debt is $3M against $4M equity (Debt-to-Equity (D/E) ratio 0.67, moderate). Current ratio is 1.47 (adequate). Debt-to-assets is 28.6%. Total assets: $10M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 90/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 36/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

NXGLW SharesGrow Score Overview

42/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 36/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NXGLW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
90/100
NXGLW: +81.2%/yr revenue is, +17.8%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet NXGLW: Debt-to-Equity (D/E) ratio 0.67 (moderate), Current ratio is 1.47 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
36/100
NXGLW: Gross margin is 39.5% (+27 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 36/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
NXGLW: Net profit margin is -26.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.04-0.314
Volume27.85K
Avg Volume (30D)6.21K
Market Cap$3.81M
Beta (1Y)1.12
Share Statistics
EPS (TTM)-0.38
Shares Outstanding$7.85M
IPO Date2021-12-22
Employees19
CEOAdam R. Levy
Financial Highlights & Ratios
Revenue (TTM)$11.42M
Gross Profit$4.51M
EBITDA$-3.35M
Net Income$-3M
Operating Income$-3.35M
Total Cash$317K
Total Debt$2.99M
Net Debt$2.67M
Total Assets$10.46M
Price / Earnings (P/E)-0.1
Price / Sales (P/S)0.33
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS65344E1156

Price Chart

Track all markets on TradingView
NXGLW
NEXGEL, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Instruments & Supplies
0.04 52WK RANGE 0.31

People Also View

NXGL
NXGL
NEXGEL, Inc.
$0.76
+27.12%
 NRSNW
NRSNW
NeuroSense Therapeutics Ltd.
$0.20
-1.00%
 CINGW
CINGW
Cingulate Inc.
$0.02
+5.00%
 KTTAW
KTTAW
Pasithea Therapeutics Corp.
$0.01
+109.86%
 NLSPW
NLSPW
NLS Pharmaceutics AG
$0.02
-20.94%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message